


SGD-1910

Cat. No.:	HY-101162
CAS No.:	1342820-51-2
Molecular Formula:	C ₆₀ H ₆₄ N ₈ O ₁₂
Molecular Weight:	1089.2
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (45.91 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	0.9181 mL	4.5905 mL	9.1811 mL
		5 mM	0.1836 mL	0.9181 mL	1.8362 mL
	10 mM	0.0918 mL	0.4591 mL	0.9181 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.5 mg/mL (0.46 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala ^[1] .
IC ₅₀ & Target	Pyrrolobenzodiazepines
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jeffrey SC, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. *Bioconjug Chem.* 2013 Jul 17;24(7):1256-63.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA